Clinical Trials Browser

Interventional × Uterine Cervical Neoplasms × temsirolimus × Clear all

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01155258 2016-06-13

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Paraganglioma, Extra-Adrenal, Pheochromocytoma, Prostatic Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT01026792 2015-09-10

Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

Phase 2 Completed

38 enrolled 5 charts

Gynecologic

Uterine Cervical Neoplasms

NCT00523432 2013-09-05

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

Phase 1 Completed

15 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Clinical Trials

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies